Dayabiitis

Uobavyuu a di muos signifikant simtom a dayabiitis

Diabetes mellitus (DM), kamanli refa tu az dayabiitis ar simpli az shuga, a wah gruup a metabalik diziiz we kiaraktaraiz bai ai blod shuga lebl uoba wah prolang piiriad. Simtom a ai blod shuga ingkluud friikuent yuurinieshan, ingkriis toers, ah ingkriis ongga. Ef ino chriit, dayabiitis kiah kaaz wuoliip a komplikieshan. Akyuut komplikieshan ingkluud dayabetik kiitoasiduosis ah nankiituotik aipoerosmuola kuoma. Siiros lang-toerm komplikieshan ingkluud kaadiovaskiula diziiz, schruok, kranik kidni fielia, fut olsa, ah damij tu di yaidem.

Dayabiitis juu tu aida di pangkrias naa projuus anof insiulin ar di seldem a di badi naa rispan prapali tu di insiulin we projuus. A chrii mien taip a diabetes mellitus:

  • Taip 1 DM rizolt frah di pangkrias fielia fi projuus anof insiulin. Dis faam eh priivosli refa tu az "insiulin-dipendant diabetes mellitus" (IDDM) ar "juuvinail dayabiitis". Di kaaz no nuo.
  • Taip 2 DM bigin wid insiulin rizistans, wah kandishan we di seldem fiel fi rispan tu insiulin propali. Az di diziiz progres lak a insiulin maita aalso divelop. Dis faam eh-priivosli refa tu az "nan insiulin-dipendant diabetes mellitus" (NIDDM) ar "adolt-anset dayabiitis". Di praimri kaaz a exesiv badi wiet ah no anof exasaiz.
  • Jestieshanal dayabiitis, a di tod mien faam ah iokor wen prignant uman widoutn priivos ischri a dayabiitis divelop ai blod-shuga lebl.

Privenshan ah chriitment invalv a elti dayat, fizikal exasaiz, mentienin naamal badi wiet, ah avaid yuus a tubako. Kanchuol a blod presha ah mentienin prapa fut kier impuotant fi piipl wid di diziiz. Taip 1 DM afi manij wid insiulin injekshan. Taip 2 DM kiah chriit wid medikieshan wid ar widoutn insiulin. Insiulin ah som uoral medikieshan kiah kaaz luo blod shuga. Wiet laas soerjri fi demde wid obiisiti somtaim a ifektiv meja ina demde wid taip 2 DM. Jestieshanal dayabiitis yuujali rizalv afta di boert a di biebi.

Az a 2015, estimietid 415 milian piipl ab dayabiitis wolwaid, wid taip 2 DM a-mekop bout 90% a di kiesdem. Dis riprizent 8.3% a di adolt papilieshan, wid iikual riet ina buot uman ah man. Frah 2012 tu 2015, dayabiitis estimiet fi eh-rizolt ina 1.5 tu 5.0 milian det iich ier. Dayabiitis akliis dobl a poersn rix a hoerli det. Di nomba a piipl wid dayabiitis expek fi riez tu 592 milian bai 2035. Di gluobal ikanamik kaas a dayabiitis ina 2014 eh-estimiet fi bi $612 bilian USD. Ina di Yunaitid Stiet, dayabiitis kaas $245 bilian ina 2012.

Causes

Komparisn a taip 1 ah 2 dayabiitis
Fiicha Taip 1 dayabiitis Taip 2 dayabiitis
Anset Sodn Grajual
Iej a anset Muosli ina pitni Muosli ina adolt
Badi saiz Maaga ar naamal Muotaim obiis
Kiitoasiduosis Kaman Rier
Aatoantibadi Yuujali prezant Absent
Indajinos insiulin Luo ar absent Naamal, dikriis

ar ingkriis

Kangkaadans

ina haidentikal tuin

50% 90%
Privalens ~10% ~90%

Refrans

  1. ↑ "About diabetes." World Health Organization. Nuoroda tikrinta 4 April 2014.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 "Diabetes Fact sheet N°312." WHO. October 2013. Nuoroda tikrinta 25 March 2014.
  3. ↑ Kitabchi, AE; Umpierrez, GE; Miles, JM; Fisher, JN (Jul 2009). "Hyperglycemic crises in adult patients with diabetes.". Diabetes Care 32 (7): 1335–43. Template:Citation error. PMID 19564476. 
  4. ↑ Shoback, edited by David G. Gardner, Dolores (2011). "Chapter 17". Greenspan's basic & clinical endocrinology (9th ed.). New York: McGraw-Hill Medical. ISBN 0-07-162243-8. 
  5. ↑ RSSDI textbook of diabetes mellitus. (Rev. 2nd ed.). New Delhi: Jaypee Brothers Medical Publishers. 2012. p. 235. ISBN 9789350254899. https://books.google.com/books?id=7H6mYolrtUMC&pg=PA235. 
  6. ↑ 6.0 6.1 "The top 10 causes of death Fact sheet N°310." World Health Organization. Oct 2013.
  7. ↑ Rippe, edited by Richard S. Irwin, James M. (2010). Manual of intensive care medicine (5th ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 549. ISBN 9780781799928. https://books.google.com/books?id=FbxupW1EHIcC&pg=PA549. 
  8. ↑ Picot, J; Jones, J; Colquitt, JL; Gospodarevskaya, E; Loveman, E; Baxter, L; Clegg, AJ (September 2009). "The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation". Health Technology Assessment (Winchester, England) 13 (41): 1–190, 215–357, iii–iv. Template:Citation error. PMID 19726018. 
  9. ↑ Cash, Jill (2014). Family Practice Guidelines (3rd ed.). Springer. p. 396. ISBN 9780826168757. https://books.google.com/books?id=nCjcAgAAQBAJ&pg=PA396. 
  10. ↑ 10.0 10.1 "Update 2015." International Diabetes Federation. Nuoroda tikrinta 21 Mar 2016.
  11. ↑ 11.0 11.1 Williams textbook of endocrinology (12th ed.). Philadelphia: Elsevier/Saunders. pp. 1371–1435. ISBN 978-1-4377-0324-5. 
  12. ↑ 12.0 12.1 Shi, Yuankai; Hu, Frank B (7 June 2014). "The global implications of diabetes and cancer". The Lancet 383 (9933): 1947–8. Template:Citation error. PMID 24910221. http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(14)60886-2. 
  13. ↑ "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010.". Lancet 380 (9859): 2163–96. Dec 15, 2012. Template:Citation error. PMID 23245607. 
  14. ↑ "Update 2014." International Diabetes Federation. Nuoroda tikrinta 29 November 2014.
  15. ↑ IDF DIABETES ATLAS (6th ed.). International Diabetes Federation. 2013. p. 7. ISBN 2930229853. http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. 
  16. ↑ American Diabetes, Association (Apr 2013). "Economic costs of diabetes in the U.S. in 2012.". Diabetes Care 36 (4): 1033–46. Template:Citation error. PMID 23468086. 
  17. ↑ "What is Type 1 Diabetes?". Medicine 30: 1–5. 2002. Template:Citation error.